Quanterix Corporation

Equities

QTRX

US74766Q1013

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
15.83 USD +0.25% Intraday chart for Quanterix Corporation -7.70% -42.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election CI
Transcript : Quanterix Corporation - Special Call
Scotiabank Raises Price Target on Quanterix to $32 From $30, Keeps Sector Outperform Rating MT
Quanterix Corporation Receives Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer?s Disease CI
Quanterix Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Quanterix Corporation, Q4 2023 Earnings Call, Feb 29, 2024
Quanterix Corporation Provides Earnings Guidance for the Year 2024 CI
Quanterix Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q4 Revenue $31.5M, vs. Street Est of $29.8M MT
Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023 CI
Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer?S Disease CI
Transcript : Quanterix Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM
Transcript : Quanterix Corporation, Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q3 Revenue $31.3M, vs. Street Est of $27.6M MT
Quanterix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q3 Revenue $31.3M, vs. Street Est of $27.6M MT
Quanterix Corporation Revises Earnings Guidance for the 2023 CI
Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease CI
Quanterix Signs License Deal for Johnson & Johnson's p-Tau 217 Antibodies, Assay Designs MT
Blood tests needed for widespread Alzheimer's diagnosis on the way RE
Transcript : Quanterix Corporation Presents at Goldman Sachs Alzheimer?s Disease Day, Oct-03-2023 12:15 PM
Goldman Sachs Raises Price Target on Quanterix to $34 From $30, Maintains Buy Rating MT
North American Morning Briefing : Yield Surge -2- DJ
Canaccord Genuity Upgrades Quanterix to Buy From Hold, Raises Price Target to $32 From $25 MT
Transcript : Quanterix Corporation Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 03:35 PM
Chart Quanterix Corporation
More charts
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.79 USD
Average target price
29.8 USD
Spread / Average Target
+88.73%
Consensus
  1. Stock Market
  2. Equities
  3. QTRX Stock
  4. News Quanterix Corporation
  5. Sector Update: Health Care Stocks Rise in Cautious Wednesday Trade